Department of Analytical Chemistry, University of Barcelona, Diagonal 647, E-08028 Barcelona, Spain.
Biochemistry and Molecular Biology Unit, Department of Biology, University of Girona, Campus Montilivi s/n, 17071 Girona, Spain.
Anal Chim Acta. 2015 Mar 25;866:59-68. doi: 10.1016/j.aca.2015.02.008. Epub 2015 Feb 7.
In this work we demonstrate the potential of glycan reductive isotope labeling (GRIL) using [(12)C]- and [(13)C]-coded aniline and zwitterionic hydrophilic interaction capillary liquid chromatography electrospray mass spectrometry (μZIC-HILIC-ESI-MS) for relative quantitation of glycosylation variants in selected glycoproteins present in samples from cancer patients. Human α1-acid-glycoprotein (hAGP) is an acute phase serum glycoprotein whose glycosylation has been described to be altered in cancer and chronic inflammation. However, it is not clear yet whether some particular glycans in hAGP can be used as biomarker for differentiating between these two pathologies. In this work, hAGP was isolated by immunoaffinity chromatography (IAC) from serum samples of healthy individuals and from those suffering chronic pancreatitis and different stages of pancreatic cancer, respectively. After de-N-glycosylation, relative quantitation of the hAGP glycans was carried out using stable isotope labeling and μZIC-HILIC-ESI-MS analysis. First, protein denaturing conditions prior to PNGase F digestion were optimized to achieve quantitative digestion yields, and the reproducibility of the established methodology was evaluated with standard hAGP. Then, the proposed method was applied to the analysis of the clinical samples (control vs. pathological). Pancreatic cancer samples clearly showed an increase in the abundance of fucosylated glycans as the stage of the disease increases and this was unlike to samples from chronic pancreatitis. The results gained here indicate the mentioned glycan in hAGP as a candidate structure worth to be corroborated by an extended study including more clinical cases; especially those with chronic pancreatitis and initial stages of pancreatic cancer. Importantly, the results demonstrate that the presented methodology combining an enrichment of a target protein by IAC with isotope coded relative quantitation of N-glycans can be successfully used for targeted glycomics studies. The methodology is assumed being suitable as well for other such studies aimed at finding novel cancer associated glycoprotein biomarkers.
在这项工作中,我们展示了使用 [(12)C]-和 [(13)C]-编码苯胺和两性离子亲水性相互作用毛细管液相色谱-电喷雾质谱 (μZIC-HILIC-ESI-MS) 的糖还原同位素标记 (GRIL) 在相对定量分析癌症患者样本中存在的选定糖蛋白中的糖基化变体方面的潜力。人 α1-酸性糖蛋白 (hAGP) 是一种急性相血清糖蛋白,其糖基化已被描述在癌症和慢性炎症中发生改变。然而,目前尚不清楚 hAGP 中的某些特定聚糖是否可以用作区分这两种病理状态的生物标志物。在这项工作中,hAGP 通过免疫亲和色谱 (IAC) 从健康个体的血清样本和分别患有慢性胰腺炎和不同阶段胰腺癌的个体的血清样本中分离出来。在去 N-糖基化后,使用稳定同位素标记和 μZIC-HILIC-ESI-MS 分析对 hAGP 聚糖进行相对定量。首先,优化了 PNGase F 消化前蛋白质变性条件,以实现定量消化产率,并使用标准 hAGP 评估了所建立方法的重现性。然后,将该方法应用于临床样本(对照与病理)的分析。胰腺癌样本明显显示出随着疾病阶段的增加,岩藻糖基化聚糖的丰度增加,这与慢性胰腺炎的样本不同。这里获得的结果表明,hAGP 中的所述聚糖是值得进一步研究(包括更多临床病例)证实的候选结构;特别是那些患有慢性胰腺炎和胰腺癌早期阶段的病例。重要的是,结果表明,所提出的方法将 IAC 对目标蛋白的富集与 N-聚糖的同位素编码相对定量相结合,可以成功地用于靶向糖组学研究。该方法也被认为适用于其他旨在寻找新型癌症相关糖蛋白生物标志物的此类研究。